Hematologic Oncology | Specialty

Combination First-line Therapy in Hairy Cell Leukemia

June 30th 2020

Determining When to Treat and First-Line Therapy for HCL

June 30th 2020

Differential Diagnosis and Molecular Tests in Identifying HCL

June 30th 2020

Signs and Tests for Diagnosis and Prognosis of HCL

June 30th 2020

Molecular Genetic Changes for Hairy Cell Leukemia

June 30th 2020

Introduction and Epidemiology of Hairy Cell Leukemia

June 30th 2020

Dr. Jacobson on the Next Steps With Axi-Cel in R/R Indolent Non-Hodgkin Lymphoma

June 29th 2020

Caron Jacobson, MD, discusses the next steps with axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Welslau on the Rationale for Rituximab Biosimilar Combination in DLBCL

June 29th 2020

Manfred Welslau, MD, discusses the rationale for investigating the Sandoz rituximab biosimilar, Rixathon, in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Neelapu on the Safety Profile of ALLO-501 Plus ALLO-647 in R/R B-Cell Lymphomas

June 29th 2020

Sattva Neelapu, MD, discusses the safety profile of ALLO-501 in combination with ALLO-647 in patients with relapsed/refractory large B-cell lymphoma or follicular lymphoma.

Belantamab Mafodotin Induces Responses in Relapsed/Refractory Myeloma, But Calls for Multidisciplinary Approach

June 29th 2020

Sagar Lonial, MD, FACP, discusses the updated data from DREAMM-2 with belantamab mafodotin, associated toxicities to be aware of, and future directions for research.

Dr. Costello on Determining Proper Dosing of Carfilzomib in Relapsed/Refractory Myeloma

June 26th 2020

Caitlin Costello, MD, discusses proper dosing of carfilzomib in relapsed/refractory multiple myeloma.

Leonard Leads Discussion on Latest Developments in Leukemias and Lymphomas

June 26th 2020

Data in Richter’s transformation, Hodgkin lymphoma, Waldenström macroglobulinemia, and indolent lymphoma were presented at the 2020 ASCO Virtual Scientific Program, and although not entirely practice changing, are deserving of attention.

Dr. Richardson on the Next Steps With CC-92480 Research in Relapsed/Refractory Multiple Myeloma

June 26th 2020

Paul G. Richardson, MD, discusses the next steps ​with the investigational cereblon E3 ligase modulator agent CC-92480 research in ​relapsed/refractory multiple myeloma.

Dr. DiNardo on the Rationale for the Pooled Analysis Evaluating Venetoclax in AML

June 26th 2020

Courtney DiNardo, MD, MSCE, discusses the rational​e for a pooled analysis evaluating venetoclax in acute myeloid leukemia.

Dr. Sharman on ​the Challenges of Adjust​ing Treatment Based on MRD Status in CLL

June 26th 2020

Jeff P. Sharman, MD, discusses the challenges of adjusting treatments based on minimal residual disease status in high-risk chronic lymphocytic leukemia.

New Strategies for Targeting CD38 in Multiple Myeloma Take Root

June 26th 2020

During the past 5 years, therapies targeting CD38, a protein highly expressed on the surface of plasma cells, have helped fuel the rapidly growing treatment options for patients with multiple myeloma.

Dr. Kuruvilla on the Safety of Pembrolizumab in Classical Hodgkin Lymphoma

June 25th 2020

John Kuruvilla, MD, FRCPC, discusses the safety of pembrolizumab (Keytruda) versus brentuximab vedotin in classical Hodgkin lymphoma.

Dr. Berdeja on Next Steps With JNJ-4528 in Relapsed/Refractory Myeloma

June 25th 2020

Jesus G. Berdeja, MD, discusses next steps for the phase 2 CARTITUDE-1 study with JNJ-4528 in relapsed/refractory myeloma.

Hill Welcomes Addition of Selinexor to DLBCL Armamentarium

June 25th 2020

The recent approval of selinexor (Xpovio) provides a novel treatment for patients with diffuse large B-cell lymphoma who have exhausted available options.

Dr. Usmani on Current Challenges in High-Risk Multiple Myeloma

June 25th 2020

Saad Z. Usmani, MD, FACP, discusses current challenges in patients with high-risk multiple myeloma.